Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    RX-5902

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rexahn Pharmaceuticals to Present at Two Upcoming Conferences
    Rexahn Pharmaceuticals to Present at Two Upcoming Conferences

    13 Mar 2018

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-present-two-upcoming-conferences

    PRESS RELEASE
    13 Mar 2018
    Share Share
    Rexahn Collab with Zhejiang Haichang Biotech for the Dev of RX-0201 Archexin®
    Rexahn Collab with Zhejiang Haichang Biotech for the Dev of RX-0201 Archexin®

    08 Feb 2018

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-announces-collaboration-zhejiang-haichang

    PRESS RELEASE
    08 Feb 2018
    Share Share
    Rexahn Receives Notice of Allowance for A New U.S. Patent-RX-5902 (Supinoxin™)
    Rexahn Receives Notice of Allowance for A New U.S. Patent-RX-5902 (Supinoxin™)

    29 Jan 2018

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-receives-notice-allowance-new-us-patent-0

    PRESS RELEASE
    29 Jan 2018
    Share Share
    Rexahn New Preclinical Data on Supinoxin™ at 2017 S.A Breast Cancer Symposium
    Rexahn New Preclinical Data on Supinoxin™ at 2017 S.A Breast Cancer Symposium

    11 Dec 2017

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-presents-new-preclinical-data-supinoxintm

    PRESS RELEASE
    11 Dec 2017
    Share Share
    Rexahn Announces $8 Million Registered Direct Offering
    Rexahn Announces $8 Million Registered Direct Offering

    13 Oct 2017

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-announces-8-million-registered-direct-offering

    PRESS RELEASE
    13 Oct 2017
    Share Share
    Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™
    Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin™

    13 Aug 2017

    // PRESS RELEASE

    http://investors.rexahn.com/news-releases/news-release-details/rexahn-pharmaceuticals-receives-new-us-patent-supinoxintm

    PRESS RELEASE
    13 Aug 2017
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.